Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Tiopronin DR, Thiola EC, Thiola,Tiopronin-K DR
Synonyms :
tiopronin
Class :
Nephrolithiasis
Dosage Forms & Strengths
Tablet
100mg
Delayed release tablets
100mg
300mg
Prevention of nephrolithiasis:
Initial dose: 800mg/day orally divided a day thrice
Based on the quantity necessary to lower urine cystine concentration to below its solubility limit (often less than 250 mg/L), the dose should be prescribed
Maintenance dose: 1000mg/day orally divided a day thrice
Dosage Forms & Strengths
Tablet
100mg
Delayed release tablets
100mg
300mg
Prevention of nephrolithiasis:
<20 kg: Safety and efficacy not established
≥20kg: 15mg/kg/day orally divided thrice daily. Do not exceed 50mg/kg/day
Modify dosage to limit urine cystine levels to around 250 mg/L.
If there has been a history of severe toxicity to d-penicillamine, start with a lower dosage
Refer adult dosing
tiopronin: they may increase the toxic effect of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
may diminish the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease the tiopronin excretion rate
may decrease triethylenetetramine elimination, raising serum levels
may decrease trifluridine elimination, raising serum levels
may decrease trimebutine elimination, raising serum levels
may decrease trimethoprim elimination, raising serum levels
may decrease triethylenetetramine elimination, raising serum levels
may decrease triethylenetetramine elimination, raising serum levels
may decrease triethylenetetramine elimination, raising serum levels
may decrease ropivacaine elimination, raising serum levels
may decrease salbutamol elimination, raising serum levels
may decrease saxagliptin elimination, raising serum levels
may decrease salicylamide elimination, raising serum levels
may decrease selenium elimination, raising serum levels
may enhance the bioavailability of tiopronin
tiopronin may decrease the excretion rate of ioxilan, potentially resulting in a higher serum level
Mechanism of action
tiopronin is a medication used primarily for the treatment of cystinuria, a genetic disorder in which excess cystine is excreted in the urine, leading to the formation of kidney stones. The exact mechanism of action of tiopronin in cystinuria has yet to be fully understood. Still, it is believed to work by binding to cystine and forming a more soluble compound, thereby preventing the formation of kidney stones
Spectrum
tiopronin has a relatively narrow spectrum of activity and is primarily used to treat cystinuria. It is ineffective against other kidney stones or urinary tract infections. In addition, tiopronin is not adequate for treating other genetic disorders that involve the build-up of amino acids in the body, such as homocystinuria or phenylketonuria
Frequency defined:
>10%
Oral ulcers (12-18%)
Nausea (12-25%)
Weakness (4-12%)
Diarrhea/soft stools (6-18%)
Fatigue (14%)
Arthralgia (12%)
Rash (12-14%)
1-10%
Proteinuria wrinkling edema (6%)
Skin (2-6%)
Anorexia pain (6%)
Peripheral (6-10%)
Fever (6%)
Emesis (10%)
Ecchymosis (8%)
Urticaria (6%)
Impotence (6%)
Cough (8%)
Abdominal (6%)
Chest (4-6%)
Anemia (6%)
Pruritus (10%)
Frequency not defined:
Hypogeusia
Reduced taste perception
Post-marketing reports:
Increased weight
Decreased appetite
Aguesia
Dizziness
Headache
Nephrotic syndrome
Renal failure
Pruritis
Skin irritation
Asthenia
Urticaria
Vomiting
Dyspepsia
Pyrexia
vertigo
Congestive heart failure
Contraindications
Caution
Pregnancy consideration: It should not be used during pregnancy, as it has been shown to cross the placenta and may harm the developing fetus
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
tiopronin is a sulfhydryl-containing medication used primarily for treating cystinuria, a genetic disorder in which excess cystine is excreted in the urine, leading to the formation of kidney stones
The exact mechanism of action of tiopronin in cystinuria is not fully understood. Still, it is believed to work by binding to cystine and forming a more soluble compound, thereby preventing the formation of kidney stones.
Pharmacodynamics
tiopronin is a medication that works primarily by binding to cystine and forming a more soluble compound, thereby preventing the formation of kidney stones in individuals with cystinuria
tiopronin has been shown to reduce urinary cystine levels and increase the solubility of cystine in the urine, which helps prevent kidney stones’ formation. The exact mechanism of action of tiopronin in cystinuria is not fully understood. Still, it is believed to involve the formation of a disulfide bond between cysteine and tiopronin, which makes cysteine more soluble
Pharmacokinetics
Absorption
It is well-absorbed after oral administration and reaches peak plasma concentrations within 1-2 hours
Distribution
It is widely distributed throughout the body, and the active metabolites are primarily excreted in the urine
Metabolism
It is rapidly metabolized in the liver to form active and inactive metabolites
Elimination and Excretion
The active metabolites of tiopronin are primarily excreted in the urine, where they bind to cystine and prevent the formation of kidney stones. The kidneys primarily eliminate tiopronin, and dosage adjustments may be necessary for individuals with renal impairment
Administration
tiopronin is usually taken orally, as a tablet or capsule. The recommended dose and frequency of tiopronin depend on the patient’s age, weight, medical condition, and response to treatment
Patient information leaflet
Generic Name: tiopronin
Pronounced: [ tye-OH-proe-nin ]
Why do we use tiopronin?
tiopronin is a medication primarily used to prevent and treat kidney stones and cystinuria.